As of 2025-03-16, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (2.96) USD. This relative valuation is based on P/E multiples. With the latest stock price at 20.79 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -114.2%.
The range of the Relative Valuation is (2.92) - (3.71) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 16.5x | 14.3x |
| Forward P/E multiples | 5.1x - 15.4x | 10.2x |
| Fair Price | (2.92) - (3.71) | (2.96) |
| Upside | -114.0% - -117.9% | -114.2% |
| Date | P/E |
| 2025-03-14 | -86.21 |
| 2025-03-13 | -79.57 |
| 2025-03-12 | -82.56 |
| 2025-03-11 | -76.71 |
| 2025-03-10 | -74.60 |
| 2025-03-07 | -73.73 |
| 2025-03-06 | -78.75 |
| 2025-03-05 | -81.07 |
| 2025-03-04 | -79.16 |
| 2025-03-03 | -79.33 |
| 2025-02-28 | -85.79 |
| 2025-02-27 | -76.67 |
| 2025-02-26 | -75.88 |
| 2025-02-25 | -75.10 |
| 2025-02-24 | -78.12 |
| 2025-02-21 | -91.72 |
| 2025-02-20 | -95.62 |
| 2025-02-19 | -89.57 |
| 2025-02-18 | -87.41 |
| 2025-02-14 | -88.61 |
| 2025-02-13 | -90.48 |
| 2025-02-12 | -81.15 |
| 2025-02-11 | -79.12 |
| 2025-02-10 | -85.01 |
| 2025-02-07 | -83.39 |
| 2025-02-06 | -85.71 |
| 2025-02-05 | -86.17 |
| 2025-02-04 | -85.50 |
| 2025-02-03 | -82.85 |
| 2025-01-31 | -89.15 |
| 2025-01-30 | -92.72 |
| 2025-01-29 | -89.73 |
| 2025-01-28 | -97.45 |
| 2025-01-27 | -97.53 |
| 2025-01-24 | -98.52 |
| 2025-01-23 | -102.22 |
| 2025-01-22 | -97.53 |
| 2025-01-21 | -91.64 |
| 2025-01-17 | -78.91 |
| 2025-01-16 | -75.43 |
| 2025-01-15 | -75.47 |
| 2025-01-14 | -69.04 |
| 2025-01-13 | -75.37 |
| 2025-01-10 | -74.02 |
| 2025-01-08 | -78.04 |
| 2025-01-07 | -75.30 |
| 2025-01-06 | -72.44 |
| 2025-01-03 | -75.64 |
| 2025-01-02 | -76.09 |
| 2024-12-31 | -74.00 |